mGlu5 Modulator Crystalline Forms for TSC Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tuberous sclerosis complex (TSC) often come with significant side effects, and there is a need for new methods that can effectively manage the condition without these adverse effects.
Innovation Solution
The use of specific crystalline forms of the compound 2-chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine or its pharmaceutically acceptable salts, such as crystalline anhydrate, monohydrate, and hemihydrate forms, administered in formulations like modified release tablets or matrix pellets, to treat TSC by acting as an mGlu5 negative allosteric modulator.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional medications such as antiepileptics are used to treat TSC, then seizures can be managed, but significant side effects occur that limit medical use
Solution Approach 1:
The patent changes the molecular parameters of the treatment agent by using a specific mGlu5 modulator compound (Formula I) with defined chemical structure, replacing conventional antiepileptic medications. This parameter change in the active ingredient's molecular properties enables effective seizure management while avoiding the harmful side effects associated with conventional drugs.
Solution Approach 2:
The patent introduces a new intermediary substance - the mGlu5 modulator compound - that acts as a mediator between the disease condition and therapeutic effect. This intermediary mechanism targets the mGlu5 receptor pathway, providing a different mode of action compared to conventional antiepileptics, thereby achieving seizure control with reduced side effects.
2Object-affected harmful factors
If new treatment methods are developed for TSC, then side effects can be reduced, but manufacturing and formulation complexity increases
Solution Approach 1:
The patent segments the formulation development into distinct crystalline forms (anhydrate, monohydrate, hemihydrate) with specific XRPD patterns and melting points. This segmentation allows systematic evaluation and selection of the most suitable form for therapeutic use, managing complexity through structured classification while achieving reduced side effects.
Solution Approach 2:
The patent employs parameter changes in the physical state of the compound by establishing specific crystalline forms with defined X-ray powder diffraction patterns and melting points. These parameter specifications enable controlled formulation development, balancing manufacturing complexity with therapeutic efficacy and safety profile.
Data Source
AI summary
Provided herein are methods of treating tuberous sclerosis complex in a subject in need thereof by administering to the subject compositions comprising an mGlu5 negative allosteric modulator (NAM), having the structure of Formula I: